BlossomHill Therapeutics, Inc.
We are on a mission to exponentially improve the number of quality years for patients.
Funding history
About BlossomHill Therapeutics, Inc.
How much funding has BlossomHill Therapeutics, Inc. raised?
BlossomHill Therapeutics, Inc. has raised $172.8M in total funding. The most recent round was Series B.
Where is BlossomHill Therapeutics, Inc. headquartered?
BlossomHill Therapeutics, Inc. is headquartered in San Diego, CA.
What does BlossomHill Therapeutics, Inc. do?
We are on a mission to exponentially improve the number of quality years for patients.
What problem does BlossomHill Therapeutics, Inc. solve?
Existing cancer therapies have limitations that leave significant unmet medical needs in cancer treatment.
What's BlossomHill Therapeutics, Inc.'s solution?
BlossomHill designs and develops small-molecule drugs, using what it calls 'The BlossomHill Way,' an intentional chemistry-based approach, to build a pipeline of clinical-stage cancer treatments (e.g., BH-30643, BH-30236).
What makes BlossomHill Therapeutics, Inc. different?
The site cites its leadership team's track record designing innovative small molecules and highlights FDA Fast Track Designation granted to BH-30643, a macrocyclic OMNI-EGFR inhibitor for a specific resistant lung cancer mutation (EGFR C797S-positive NSCLC).
What makes BlossomHill Therapeutics, Inc. notable?
Founded by Jean Cui, a former Pfizer chemist, and has raised over $250 million from investors including Janus Henderson and Cormorant Asset Management.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.